Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JANX NASDAQ:KROS NASDAQ:REPL NASDAQ:TBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJANXJanux Therapeutics$13.56-0.7%$14.51$12.12▼$35.34$833.05M2.53889,400 shs860,404 shsKROSKeros Therapeutics$10.15+1.0%$11.26$9.69▼$22.55$198.91M0.94272,016 shs178,205 shsREPLReplimune Group$8.88+3.0%$5.25$1.50▼$13.24$711.78M0.916.86 million shs1.97 million shsTBPHTheravance Biopharma$16.64+0.9%$16.46$10.42▼$21.03$850.11M0.17364,896 shs230,170 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJANXJanux Therapeutics+3.88%-0.73%-5.20%+0.59%-46.35%KROSKeros Therapeutics+1.21%-6.69%-13.73%-8.80%-27.12%REPLReplimune Group+1.77%-12.66%+110.76%+20.73%-11.86%TBPHTheravance Biopharma+0.73%+0.73%+0.06%+19.67%+55.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJANXJanux Therapeutics$13.56-0.7%$14.51$12.12▼$35.34$833.05M2.53889,400 shs860,404 shsKROSKeros Therapeutics$10.15+1.0%$11.26$9.69▼$22.55$198.91M0.94272,016 shs178,205 shsREPLReplimune Group$8.88+3.0%$5.25$1.50▼$13.24$711.78M0.916.86 million shs1.97 million shsTBPHTheravance Biopharma$16.64+0.9%$16.46$10.42▼$21.03$850.11M0.17364,896 shs230,170 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJANXJanux Therapeutics+3.88%-0.73%-5.20%+0.59%-46.35%KROSKeros Therapeutics+1.21%-6.69%-13.73%-8.80%-27.12%REPLReplimune Group+1.77%-12.66%+110.76%+20.73%-11.86%TBPHTheravance Biopharma+0.73%+0.73%+0.06%+19.67%+55.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJANXJanux Therapeutics 2.60Moderate Buy$45.85238.10% UpsideKROSKeros Therapeutics 2.25Hold$20.40100.99% UpsideREPLReplimune Group 1.70Reduce$4.88-45.10% DownsideTBPHTheravance Biopharma 2.50Moderate Buy$21.8331.21% UpsideCurrent Analyst Ratings BreakdownLatest KROS, JANX, REPL, and TBPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026TBPHTheravance Biopharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/1/2026REPLReplimune Group WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$2.00 ➝ $6.005/29/2026REPLReplimune Group JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$8.005/27/2026TBPHTheravance Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/15/2026KROSKeros Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/11/2026JANXJanux Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$22.005/8/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026TBPHTheravance Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/8/2026JANXJanux Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$30.00 ➝ $26.005/8/2026JANXJanux Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$45.00 ➝ $36.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJANXJanux Therapeutics$10M82.69N/AN/A$15.91 per share0.85KROSKeros Therapeutics$244.06M0.82$4.57 per share2.22$15.51 per share0.65REPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ATBPHTheravance Biopharma$107.46M7.98N/AN/A$5.86 per share2.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJANXJanux Therapeutics-$113.62M-$1.84N/AN/AN/AN/A-12.93%-12.23%8/6/2026 (Estimated)KROSKeros Therapeutics$87.01M-$3.01N/AN/AN/A-256.60%-17.04%-15.84%8/5/2026 (Estimated)REPLReplimune Group-$247.30M-$3.44N/AN/AN/AN/A-102.69%-72.22%6/12/2026 (Estimated)TBPHTheravance Biopharma$105.89M$2.207.5659.43N/A104.34%18.84%10.94%8/11/2026 (Estimated)Latest KROS, JANX, REPL, and TBPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/12/2026Q4 2026REPLReplimune Group-$0.73N/AN/AN/A$5.57 millionN/A5/14/2026Q1 2026KROSKeros Therapeutics-$1.0229-$1.21-$0.1871-$1.21$1.93 million$0.37 million5/7/2026Q1 2026JANXJanux Therapeutics-$0.5202-$0.39+$0.1302-$0.39$4.36 million$3.73 million5/7/2026Q1 2026TBPHTheravance Biopharma$0.0280-$0.10-$0.1280-$0.10$17.78 million$17.70 million3/31/2026Q4 2025TBPHTheravance BiopharmaN/A-$0.10N/A-$0.10N/A$17.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthJANXJanux TherapeuticsN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJANXJanux TherapeuticsN/A17.0117.01KROSKeros TherapeuticsN/A22.6122.62REPLReplimune Group0.335.605.60TBPHTheravance BiopharmaN/A13.1413.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJANXJanux Therapeutics75.39%KROSKeros Therapeutics71.56%REPLReplimune Group92.53%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipJANXJanux Therapeutics7.90%KROSKeros Therapeutics20.60%REPLReplimune Group5.20%TBPHTheravance Biopharma7.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJANXJanux Therapeutics3060.98 million56.17 millionOptionableKROSKeros Therapeutics10019.79 million15.72 millionOptionableREPLReplimune Group21082.57 million78.28 millionOptionableTBPHTheravance Biopharma11051.55 million47.61 millionOptionableKROS, JANX, REPL, and TBPH HeadlinesRecent News About These CompaniesTBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline HurdleMay 8, 2026 | zacks.comHere's Why Theravance Biopharma (TBPH) is a Strong Momentum StockMay 7, 2026 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHMay 7, 2026 | prnewswire.comTheravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 7, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 28, 2026 | globenewswire.comLaughing Water Capital’s New Position: Theravance Biopharma, Inc. (TBPH)April 25, 2026 | insidermonkey.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance ...April 21, 2026 | bakersfield.comBINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 21, 2026 | globenewswire.comB. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14April 20, 2026 | insidermonkey.com8 Most Undervalued Biotech Stocks to Buy Right NowApril 18, 2026 | insidermonkey.comTheravance Stock Declines Around 17% in Three Months: Here's WhyApril 16, 2026 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 16, 2026 | prnewswire.comHere's Why Theravance Biopharma (TBPH) is a Strong Momentum StockApril 15, 2026 | zacks.comTBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP InvestigatesApril 15, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 14, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Theravance Biopharma (TBPH)April 10, 2026 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 9, 2026 | prnewswire.comTBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law FirmApril 2, 2026 | businesswire.com5 Small Drug Stocks to Buy as Sector Recovery Gains StrengthApril 2, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026The Power Grid Is Dying—Is It Time to Buy Its Replacement?By Jeffrey Neal Johnson | May 15, 2026KROS, JANX, REPL, and TBPH Company DescriptionsJanux Therapeutics NASDAQ:JANX$13.56 -0.10 (-0.73%) Closing price 04:00 PM EasternExtended Trading$13.57 +0.01 (+0.10%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Keros Therapeutics NASDAQ:KROS$10.15 +0.10 (+1.00%) Closing price 04:00 PM EasternExtended Trading$10.15 +0.00 (+0.05%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Replimune Group NASDAQ:REPL$8.88 +0.26 (+3.02%) Closing price 04:00 PM EasternExtended Trading$8.85 -0.04 (-0.39%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Theravance Biopharma NASDAQ:TBPH$16.64 +0.15 (+0.91%) Closing price 04:00 PM EasternExtended Trading$16.64 +0.00 (+0.03%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
